Resources

December 2019 Corporate Update

Harold H. Shlevin, Ph.D., president and chief executive officer of Galectin Therapeutics, provided an update on plans for the NASH-RX clinical trial of belapectin in patients with NASH cirrhosis without esophageal varices.

Galectin Therapeutics presentation at 2019 Anti-Fibrotic Drug Development (AFDD) Summit

Eliezer Zomer, Ph.D., Vice President, Discovery Research and Product Development for Galectin Therapeutics, presented at the 3rd Annual Anti-Fibrotic Drug Development (AFDD) Summit, held from Nov 18 – 20, 2019 in Boston, Massachusetts.

Corporate Update

An updated overview of the company’s activities and Clinical Phase studies with the galectin‑3 inhibitor GR‑MD‑02.

Corporate Update - Thumbnail

The Liver Line

The Liver Line is a community and online publication on liver health and liver disease. Liver Line is a central gathering place for patients, medical professionals and researchers to learn about the latest research in liver health and the treatment of diseases such as non-alcoholic steatohepatitis (NASH), liver fibrosis, and cirrhosis.

The Liver Line